General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold - PubMed (original) (raw)
. 2009 Jan 30;284(5):3273-3284.
doi: 10.1074/jbc.M806889200. Epub 2008 Nov 14.
Affiliations
- PMID: 19010777
- DOI: 10.1074/jbc.M806889200
Free article
General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold
Cécile Vincke et al. J Biol Chem. 2009.
Free article
Abstract
Nanobodies, single-domain antigen-binding fragments of camelid-specific heavy-chain only antibodies offer special advantages in therapy over classic antibody fragments because of their smaller size, robustness, and preference to target unique epitopes. A Nanobody differs from a human heavy chain variable domain in about ten amino acids spread all over its surface, four hallmark Nanobody-specific amino acids in the framework-2 region (positions 42, 49, 50, and 52), and a longer third antigen-binding loop (H3) folding over this area. For therapeutic applications the camelid-specific amino acid sequences in the framework have to be mutated to their human heavy chain variable domain equivalent, i.e. humanized. We performed this humanization exercise with Nanobodies of the subfamily that represents close to 80% of all dromedary-derived Nanobodies and investigated the effects on antigen affinity, solubility, expression yield, and stability. It is demonstrated that the humanization of Nanobody-specific residues outside framework-2 are neutral to the Nanobody properties. Surprisingly, the Glu-49 --> Gly and Arg-50 --> Leu humanization of hallmark amino acids generates a single domain that is more stable though probably less soluble. The other framework-2 substitutions, Phe-42 --> Val and Gly/Ala-52 --> Trp, are detrimental for antigen affinity, due to a repositioning of the H3 loop as shown by their crystal structures. These insights were used to identify a soluble, stable, well expressed universal humanized Nanobody scaffold that allows grafts of antigen-binding loops from other Nanobodies with transfer of the antigen specificity and affinity.
Similar articles
- In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.
Vaneycken I, Govaert J, Vincke C, Caveliers V, Lahoutte T, De Baetselier P, Raes G, Bossuyt A, Muyldermans S, Devoogdt N. Vaneycken I, et al. J Nucl Med. 2010 Jul;51(7):1099-106. doi: 10.2967/jnumed.109.069823. Epub 2010 Jun 16. J Nucl Med. 2010. PMID: 20554727 - A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops.
Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L. Decanniere K, et al. Structure. 1999 Apr 15;7(4):361-70. doi: 10.1016/s0969-2126(99)80049-5. Structure. 1999. PMID: 10196124 - Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies.
Muyldermans S, Lauwereys M. Muyldermans S, et al. J Mol Recognit. 1999 Mar-Apr;12(2):131-40. doi: 10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M. J Mol Recognit. 1999. PMID: 10398404 - Single domain camel antibodies: current status.
Muyldermans S. Muyldermans S. J Biotechnol. 2001 Jun;74(4):277-302. doi: 10.1016/s1389-0352(01)00021-6. J Biotechnol. 2001. PMID: 11526908 Review. - Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E, Morales-Yanez F, Hu Y, Crauwels M, De Pauw P, Hassanzadeh GG, Devoogdt N, Ackaert C, Vincke C, Muyldermans S. Romao E, et al. Curr Pharm Des. 2016;22(43):6500-6518. doi: 10.2174/1381612822666160923114417. Curr Pharm Des. 2016. PMID: 27669966 Review.
Cited by
- Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.
Wang Z, Zhou L, Wu X. Wang Z, et al. Oncol Res. 2024 Aug 23;32(9):1479-1516. doi: 10.32604/or.2024.048564. eCollection 2024. Oncol Res. 2024. PMID: 39220130 Free PMC article. Review. - Construction and validation of a synthetic phage-displayed nanobody library.
Kim M, Bai X, Im H, Yang J, Kim Y, Kim MM, Oh Y, Jeon Y, Kwon H, Lee S, Lee CH. Kim M, et al. Korean J Physiol Pharmacol. 2024 Sep 1;28(5):457-467. doi: 10.4196/kjpp.2024.28.5.457. Korean J Physiol Pharmacol. 2024. PMID: 39198226 Free PMC article. - Development of novel humanized VHH synthetic libraries based on physicochemical analyses.
Nakakido M, Kinoshita S, Tsumoto K. Nakakido M, et al. Sci Rep. 2024 Aug 22;14(1):19533. doi: 10.1038/s41598-024-70513-4. Sci Rep. 2024. PMID: 39174623 Free PMC article. - Bi-specific antibody engagers for cancer immunotherapy.
Ploegh H, Liu X, Le Gall C, Alexander R, Borgman E, Balligand T. Ploegh H, et al. Res Sq [Preprint]. 2024 Aug 1:rs.3.rs-4792057. doi: 10.21203/rs.3.rs-4792057/v1. Res Sq. 2024. PMID: 39149504 Free PMC article. Preprint. - Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases.
Weibel N, Curcio M, Schreiber A, Arriaga G, Mausy M, Mehdy J, Brüllmann L, Meyer A, Roth L, Flury T, Pecina V, Starlinger K, Dernič J, Jungfer K, Ackle F, Earp J, Hausmann M, Jinek M, Rogler G, Antunes Westmann C. Weibel N, et al. ACS Synth Biol. 2024 Aug 16;13(8):2376-2390. doi: 10.1021/acssynbio.4c00036. Epub 2024 Aug 8. ACS Synth Biol. 2024. PMID: 39115381 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases